SemaThera Inc

SemaThera Inc., located in Westmount, QC, is dedicated to developing innovative treatments for diabetic and other retinal degenerative diseases. The company has emerged from over a decade of research led by Professor Przemyslaw Mike Sapieha, focusing on the role of semaphorins, particularly semaphorin 3A, in these conditions. Through the creation of biological traps designed to bind and sequester semaphorin 3A and related cytokines, SemaThera aims to mitigate the effects of diabetic retinopathy. Their studies have demonstrated the potential of these traps to reduce retinal vascular leakage, inflammation, and promote physiological revascularization in various models of retinal vascular diseases. Generated from the website

Theratechnologies Inc. is a biopharmaceutical company based in Montréal, Quebec, dedicated to the development and commercialization of innovative therapies, primarily for individuals living with HIV. The company currently markets two prescription products, Trogarzo and EGRIFTASV, in the United States and is focused on addressing unmet medical needs in both HIV and oncology. In addition to its marketed products, Theratechnologies is advancing its pipeline, which includes the F8 formulation of tesamorelin for HIV-associated lipodystrophy and ongoing clinical trials utilizing its proprietary SORT1 Technology in oncology. The company aims to make a significant impact on patient lives through its commitment to health innovation. Generated from the website